Objective: To analyze the clinical therapeutic effect and safety of recombinant bovine basic fibroblast growth factor (rb-bFGF) gel combined with fractional laser technology in the treatment of facial acne atrophic scars. Methods: Eighty patients with facial acne atrophic scars who were treated in the dermatology department of our hospital from January 2023 to January 2025 were selected. They were randomly divided into the observation group (n=40) and the control group (n=40) using a random number table. The control group received treatment with fractional laser alone, while the observation group received treatment with fractional laser combined with topical application of recombinant bovine basic fibroblast growth factor gel. The clinical efficacy, scar improvement-related indicators, and skin barrier function indicators of the two groups were compared. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05); 3 months after treatment, the scar improvement-related indicators and skin barrier function indicators of the observation group were better than those of the control group (P<0.05). Conclusion: The use of recombinant bovine basic fibroblast growth factor gel combined with fractional laser therapy for patients with facial acne atrophic scars can improve the appearance of the scars and the skin barrier function of the patients. Keywords: Recombinant bovine basic fibroblast growth factor gel; Fractional laser; Facial acne